Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas

Purpose: The aim of this study is to investigate the genetic heterogeneity (carcinomatous vs. sarcomatous components) and predictive biomarkers in patients with pulmonary sarcomatoid carcinoma (PSC). Methods: Genetic alterations and biomarkers of immunotherapy were performed in a discovery set (n = 6) of PSC. Next-generation sequencing (NGS) on a pan-cancer gene panel was applied to detect the genetic alterations in each component, and the respective mutation profiling and tumor mutation burden (TMB) were compared as well. Immunohistochemistry (IHC) assay with SP263 antibody was used to detect the protein expression of programmed death-ligand 1 (PD-L1) in each component. Results: Comparative genetic analysis revealed that the separate carcinomatous and sarcomatous components shared strikingly common mutations. TP53 (4/6, 66.7%) was the most common genetic alteration in 6 PSC patients. MET exon 14 skipping was detected in one case, accounting for 16.7%. An EZR-ROS1 fusion (EZR: intron10-ROS1: intron32) was identified in one case. The TMB of the two components was similar. Nevertheless, significantly higher PD-L1 expression was found in carcinomatous components compared to sarcomatous components. MDM2 amplification was detected in 2/6 (33.3%) of cases and SIK11 mutation in 1/6 (16.7%) of cases. Conclusions: PSC containing carcinomatous and sarcomatous components had a mild heterogeneity; the two components may evolve from common ancestral cells. High PD-L1 expression suggests that immunotherapy could be used as a potential therapy for PSC patients, while patients with negative immune-responsive genes need to be screened out. Altogether, these findings further highlight that the detection of genetic alteration and PD-Ll expression plays an important role in treatment of patients with PSC. (C) 2020 Elsevier Inc. All rights reserved.

Automated summary

Genetic heterogeneity and predictive biomarkers were investigated in patients with pulmonary sarcomatoid carcinoma (PSC). The study found common mutations between the carcinomatous and sarcomatous components, as well as significantly higher PD-L1 expression in the carcinomatous components. High PD-L1 expression suggests potential efficacy of immunotherapy for PSC patients, emphasizing the importance of genetic alteration and PD-L1 expression detection in treatment.